What to include in a clinical trial referral letter to physicians

Why does the referral letter matter so much?

Physicians and nurses cite the inability to access information and insufficient information and time as key reasons they do not refer patients to trials (Tufts CSDD via Applied Clinical Trials). A well built letter solves both problems at once: it delivers the study information, and it can be read and acted on in a couple of minutes.

What should a clinical trial referral letter include?

1. A one sentence study summary. The condition, the phase, and what is being studied, in plain clinical terms.
2. The deciding eligibility criteria. Three to five inclusion and exclusion points that rule most patients in or out. Leave the full protocol for the coordinator call.
3. The site and investigator. Site name, address, and principal investigator, so the physician knows exactly where the patient would go.
4. The exact referral steps. A named coordinator with a direct phone number and email. One step, not a web form maze.
5. What the patient can expect. Visit frequency and study length, stated factually, so the physician can judge fit.
6. A commitment to close the loop. Nearly 30% of physicians reported never hearing from site staff after a referral (Tufts CSDD). Say in writing that you will report back.
7. A way to respond fast. A QR code unique to each physician lets them reach the study page in seconds and lets the site see who engaged.

What should you leave out of the letter?

• Marketing language. Physicians respond to specifics, not slogans.
• Promises of benefit. Describe the study; do not imply outcomes.
• Any payment for referrals. The AMA Code of Medical Ethics treats payment solely for referring a patient to a research study as unethical fee splitting (AMA). See finder's fees explained.

Does a physician referral letter need IRB approval?

Usually not under FDA guidance. FDA's guidance on recruiting study subjects says the direct advertising that IRBs review does not include communications intended for health professionals, such as "dear doctor" letters and doctor to doctor letters, even when they solicit study subjects (FDA). Based on that guidance, WCG IRB does not require prior review of doctor to doctor letters (WCG).

Two cautions. First, your IRB can set stricter rules, so confirm its written policy. Second, anything intended for patients, such as a flyer a physician places in the waiting room, is direct advertising under the same FDA guidance and does need IRB review.

How should the letter be formatted?

One page, printed on quality paper, addressed to the physician by name. Put the study summary and referral contact above the fold so a physician scanning between patients sees both. If you are reaching several specialties, write a version for each one that uses the language that specialty uses for the condition.

What happens after the letter is mailed?

A letter is the opening, not the whole campaign. Follow up by email and LinkedIn within the next few weeks, prioritizing physicians whose QR codes show they engaged. Physicians refer a median of five patients into trials per year (Getz, Applied Clinical Trials), so consistent, relevant contact is what moves your study into that short list.